- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02090348
Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate (TECNERGY)
September 3, 2015 updated by: Biogen
A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing-Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsules (TECNERGY)
The primary objective of this study is to determine whether dimethyl fumarate (DMF) taken over 12 months is effective in reducing Multiple Sclerosis (MS)-related fatigue, as measured by mean changes in the Fatigue Scale for Motor and Cognitive Functions (FSMC), in participants with relapsing-remitting multiple sclerosis (RRMS).
The secondary objectives of this study are: To investigate changes from Baseline in FSMC and fatigue severity (Fatigue Severity Scale [FSS]) at 1, 3, 6, 9, and 12 months in participants receiving DMF; To assess the impact of DMF on patient-reported outcomes (PROs), including work productivity (Work Productivity and Activity Impairment-Multiple Sclerosis questionnaire [WPAI-MS]), health-related quality of life (Short Form Health Survey [SF-12]), depression (Beck Depression Inventory-Fast Screen [BDI-FS]), and sleepiness (Epworth Sleepiness Scale [ESS]) at 6 and 12 months in participants receiving DMF; To examine whether an association exists between fatigue and baseline demographics (e.g., age and sex) and disease characteristics (e.g., disease duration, baseline disease activity, treatment history, expanded disability status scale [EDSS] score, and PROs); To assess any changes in fatigue-related medication use.
Study Overview
Status
Withdrawn
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Have a confirmed diagnosis of RRMS and satisfies the therapeutic indication as described in the local label.
- Have a stable EDSS (as assessed by the Investigator) and been on the same (type and dosage) standard of care (SOC) first-line treatment for at least 6 months.
- If taking antidepressants, amphetamine, modafinil, or fampridine (Fampyra), subject must be assessed as having been clinically stable for at least 3 months prior to the Baseline Visit.
- FSMC total score ≥43 (mild fatigue) at Baseline.
- As perceived by the Investigator, have the ability to comply with all requirements of the study protocol.
Key Exclusion Criteria:
- Diagnosis of major depression, as identified by the Investigator.
- Diagnosis of primary progressive, secondary progressive, or progressive relapsing multiple sclerosis.
- History of malignancy (except for basal cell carcinoma that had been completely excised prior to study entry), severe allergic or anaphylactic reactions or known drug hypersensitivity, abnormal laboratory results indicative of any significant disease, and/or a major disease that would preclude participation in a clinical trial.
- Treatment of MS relapse within 90 days prior to study enrollment.
- History of a positive test result for human immunodeficiency virus, hepatitis C virus antibody, or hepatitis B virus (defined as positive for hepatitis B surface antigen or hepatitis B core antibody.
- Impaired hepatic or renal function, as perceived by the Investigator.
- Any prior treatment with DMF (or other fumarate derivative), total lymphoid irradiation, cladribine, fingolimod, T cell or T-cell receptor vaccination, or any therapeutic monoclonal antibody.
- Current enrollment in any other clinical studies.
- Known to suffer from narcolepsy or another significant sleep disorder.
- Comorbidity that may have an impact on fatigue.
- Other unspecified reasons that, in the opinion of the Investigator or Biogen Idec, make the subject unsuitable for enrollment.
NOTE: Other protocol-defined Inclusion/Exclusion Criteria May Apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: dimethyl fumarate
DMF at a dose of 120 mg twice a day (BID) for the first 7 days and 240 mg BID for the remainder of study period (up to 12 months)
|
Administered as specified in the treatment arm
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change from baseline in MS-related fatigue as assessed by FSMC at 12 months in participants receiving DMF
Time Frame: 12 months
|
FSMC is a 20-item questionnaire and produces a score between 1 and 5 for each scored question (ranging from "does not apply at all" to "applies completely").
Items are summed to generate a total score and transformed to a scale with a range of 20 to 100, where higher scores indicate higher levels of fatigue
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change from baseline in fatigue as assessed by FSMC in participants receiving DMF
Time Frame: Baseline and 1, 3, 6, 9 and 12 months
|
Baseline and 1, 3, 6, 9 and 12 months
|
|
Mean change from baseline in fatigue as assessed by FSS in participants receiving DMF
Time Frame: Baseline and 1, 3, 6, 9 and 12 months
|
The Fatigue Severity Scale (FSS) is designed to differentiate fatigue from clinical depression, since both share some of the same symptoms.
FSS consists of answering a 9-item questionnaire that requires the participant to rate his or her own level of fatigue.
Each question produces a score between 1 to 7. The scoring is done by calculating the average response to the questions.
Participants with depression alone score about 4.5.
But people with fatigue related to MS average about 6.5
|
Baseline and 1, 3, 6, 9 and 12 months
|
Mean change from baseline in work productivity as assessed by WPAI-MS, in participants receiving DMF
Time Frame: Baseline and 6, 12 months
|
The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated instrument to measure impairments in work and activities.
The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity
|
Baseline and 6, 12 months
|
Mean change from baseline in quality of life as assessed by SF-12 in participants receiving DMF
Time Frame: Baseline and 6, 12 months
|
The SF-12 is a multipurpose short form survey with 12 questions, all selected from the SF-36 Health Survey.
The questions were combined, scored, and weighted to create two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life.
Physical and Mental Health Composite Scores (PCS & MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health and 100 indicates the highest level of health
|
Baseline and 6, 12 months
|
Mean change from baseline in depression as assessed by BDI-FS in participants receiving DMF
Time Frame: Baseline and 6, 12 months
|
BDI-FS is a self-report inventory for measuring the severity of depression on a 7-item questionnaire.
Each question is rated on a 4-point scale (0 - 3) to assess frequency, over the past two weeks, of feelings of sadness, pessimism (hopelessness), sense of failure, loss of a sense of pleasure, loss of self-confidence, self-blame, and suicidal ideation.
The total ESS score is the sum of 8 item-scores and can range between 0 and 21, where higher scores indicate higher levels of depression
|
Baseline and 6, 12 months
|
Mean change from baseline in sleepiness assessed by ESS in participants receiving DMF
Time Frame: Baseline and 6, 12 months
|
The ESS is a self-administered 8-item questionnaire with that provides a measure of a person's general level of daytime sleepiness, or their average sleep propensity in daily life.
Each question is rated on a 4-point scale (0 - 3), their usual chances of dozing off or falling asleep in 8 different situations or activities that most people engage in as part of their daily lives, although not necessarily every day.
The total ESS score is the sum of 8 item-scores and can range between 0 and 24, where higher scores indicate higher levels of a person's level of daytime sleepiness
|
Baseline and 6, 12 months
|
Change in MS-related fatigue (FSMC) status
Time Frame: Baseline and up to 12 months
|
Improved (> 4.5 increase), Stable (within ±4.5), and Worsened (> 4.5 decrease)
|
Baseline and up to 12 months
|
Correlation of fatigue with baseline demographics and disease characteristics
Time Frame: Baseline and up to 12 months
|
Baseline and up to 12 months
|
|
Proportion of participants with reduced dose or discontinuation of fatigue-related medications
Time Frame: 6 and 12 months
|
6 and 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2015
Primary Completion (Anticipated)
October 1, 2017
Study Completion (Anticipated)
October 1, 2017
Study Registration Dates
First Submitted
March 14, 2014
First Submitted That Met QC Criteria
March 14, 2014
First Posted (Estimate)
March 18, 2014
Study Record Updates
Last Update Posted (Estimate)
September 7, 2015
Last Update Submitted That Met QC Criteria
September 3, 2015
Last Verified
September 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Physiological Effects of Drugs
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Dimethyl Fumarate
Other Study ID Numbers
- 109MS405
- 2013-001025-53 (EudraCT Number)
- DEN-BGT-13-10413 (Other Identifier: Biogen)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on dimethyl fumarate
-
BiogenCompleted
-
Xuanwu Hospital, BeijingTerminatedAcute Ischemic StrokeChina
-
BiogenCompletedMultiple Sclerosis | Multiple Sclerosis, Relapsing-RemittingFrance
-
Almirall, S.A.Completed
-
Beijing Tiantan HospitalBeijing Chao Yang Hospital; Henan Provincial People's Hospital; Beijing Neurosurgical...Not yet recruitingIntracranial Aneurysm | Aneurysm, Brain | Inflammation VascularChina
-
University at BuffaloCompletedMultiple Sclerosis, Dimethyl Fumarate, Diffusion Tensor Imaging Magnetic Resonance Imaging
-
Fondation Ophtalmologique Adolphe de RothschildTerminatedMonitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate (SURV-SEP)Multiple Sclerosis, Relapsing-RemittingFrance
-
Genesis Pharma CNS & SpecialtyCompleted
-
BiogenCompletedMultiple Sclerosis, Relapsing-RemittingPoland, Turkey, United States, Latvia, Lebanon, Germany, Belgium, Bulgaria, Czechia, Kuwait
-
Banner Life Sciences LLCCompletedMultiple SclerosisUnited States